Back to results
US 7,030,116 B2Granted
Compounds and compositions as cathepsin inhibitors
AssigneesAventis Pharmaceuticals Inc., Axys Pharmaceuticals, Inc.
InventorsMichael Graupe, James T. Palmer, John W. Patterson, David J. Aldous, Sukanthini Thurairatnam, Andreas P. Timm, John Link, Jiayao Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
Claims9
A compound of formula I,
- wherein X2 is a sulfonyl alkyl motif selected from the group consisting of,
- X3 is a heterocyclic motif or an amide motif, wherein the heterocyclic motif is selected the group consisting of
- and the amide motif is selected from the group consisting of
- X7 is —H, X4 is an alkyl group with straight or branched-chain containing 1–4 carbon atoms or
- and X5 is —H, —F, —OH, or —O—R, and R is an alkyl group with straight or branched-chain containing 1–6 carbon.
2 more elements
A compound selected from the group consisting of:
- 2-(2-Methyl-propane-1-sulfonylmethyl)-4-morpholin-4-yl-4-oxo-N-[(S)-1-(5-phenyl-1,2,4-oxadiazole-3-carbonyl)-propyl]-butyramide,
- 4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-N-[(S)-1-(5-trifluoromethyl-1,2,4-oxadiazole-3-carbonyl)-propyl]-butyramide,
- (R)-2-(2-Methyl-propane-1-sulfonylmethyl)-4-morpholin-4-yl-4-oxo-N-[(S)-1-(3-phenyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-butyramide,
- N-[(S)-1-(5-Ethyl-1,2,4-oxadiazole-3-carbonyl)-propyl]-4-morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-butyramide,
- (R)-4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-N-[(S)-1-(3-phenyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-butyramide,
- (R)-4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-N-[1-(3-phenyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-butyramide,
- (R)-N-[(S)-1-(3-Cyclopropyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-2-(2-methyl-prapane-1-sulfonylmethyl)-4-morpholin-4-yl-4-oxo-butyramide,
- (R)-2-Cyclopropylmethanesulfonylmethyl-N-[(S)-1-(3-cyclopropyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-4-morpholin-4-yl-4-oxo-butyramide,
- (R)-N-[(S)-1-(3-Ethyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-2-(2-methyl-propane-1-sulfonylmethyl)-4-morpholin-4-yl-4-oxo-butyramide,
- (R)-2-Cyclopropylmethanesulfonylmethyl-N-[(S)-1-(3-ethyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-4-morpholin-4-yl-4-oxo-butyramide,
- (S)-2-(2-Benzenesulfonyl-ethyl)-N-[(S)-1-(3-ethyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-4-morpholin-4-yl-4-oxo-butyramide,
- (S)-N-[(S)-1-(3-Ethyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-4-morpholin-4-yl-4-oxo-2-[2-(propane-2-sulfonyl)-ethyl]-butyramide,
- (S)-3-(4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-butyrylamino)-2-oxo-pentanoic acid (pyridin-4-ylmethyl)-amide,
- (S)-3-(4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-butyrylamino)-2-oxo-pentanoic acid diethylamide,
- (S)-3-(4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-butyrylamino)-2-oxo-pentanoic acid phenethyl-amide, and
- (S)-3-(4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-butyrylamino)-2-oxo-pentanoic acid (2-pyridin-2-yl-ethyl)-amide.
13 more elements
A compound selected from the group consisting of:
- 2-(2-Methyl-propane-1-sulfonylmethyl)-4-morpholin-4-yl-4-oxo-N-[(S)-1-(5-phenyl-1,2,4-oxadiazole-3-carbonyl)-propyl]-butyramide and
- (R)-4-Morpholin-4-yl-4-oxo-2-phenylmethanesulfonylmethyl-N-[(1-(3-phenyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-butyramide.
Dependencies are inferred from the claim text.